Advertisement

Topics

Puma's Nerlynx Edges Out Novartis' Tykerb in Breast Cancer Trial

20:00 EDT 16 May 2019 | BioSpace

Patients were randomized 1:1 to receive Nerlynx and Xeloda or Tykerb and Xeloda. Co-primary endpoints were progression-free survival and overall survival.

Original Article: Puma's Nerlynx Edges Out Novartis' Tykerb in Breast Cancer Trial

NEXT ARTICLE

More From BioPortfolio on "Puma's Nerlynx Edges Out Novartis' Tykerb in Breast Cancer Trial"

Advertisement
Quick Search
Advertisement
Advertisement